spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  exenatide 

 HSMN NewsFeed - 10 Dec 2020
Rani Therapeutics Raises $69 Million Series E To Advance Clinical Trials And Manufacturing Of Robotic Pill
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
Biopharmaceuticals Endocrinology Product Launch
 HSMN NewsFeed - 18 Apr 2017
Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
Biopharmaceuticals Gastroenterology Surgery Personnel
 HSMN NewsFeed - 1 Feb 2017
Glide Technologies Announces Successful £3.2 Million ($4.0 Million) Fundraising
Devices Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 31 Oct 2016
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2016
Flamel Technologies Launches Akovaz(TM)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 30 Jun 2016
OPKO Health to Acquire Transition Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Jan 2016
Antares Pharma Announces CEO Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2015
Antares Pharma Announces FDA Approval of Sumatriptan Injection USP
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jul 2015
Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA
 HSMN NewsFeed - 19 Dec 2013
Bristol-Myers Squibb Continues Evolution to Specialty BioPharma Through Sale of Its Diabetes Business
Biopharmaceuticals Endocrinology Acquisitions
 HSMN NewsFeed - 17 Sep 2013
DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2013
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Jul 2013
Intarcia Therapeutics Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 23 Mar 2012
BYETTA(R) Approved for Use with Basal Insulin in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 8 Nov 2011
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2011
Bydureon Receives Marketing Authorization in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 16 May 2011
Lilly Provides Its Perspective in Response to Amylin Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 May 2011
Lilly Provides Statement in Response to Amylin Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 May 2011
Amylin Pharmaceuticals Files Suit Against Eli Lilly
Biopharmaceuticals Litigation
 HSMN NewsFeed - 15 Apr 2011
BYDUREON Recommended for Approval in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 1 Jun 2010
Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2010
Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in a Key Phase III Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Apr 2010
Paul Westberg Joins Versartis as Senior Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2010
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
Biopharmaceuticals
 HSMN NewsFeed - 22 Feb 2010
Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2009
Versartis, Inc. Completes Series A Funding of $11 Million [EUR 7.9 M] in a Joint Venture Between Index Ventures and Amunix, Inc.
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Apr 2009
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 26 Mar 2009
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 26 Jan 2009
Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2007
Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 1 Oct 2007
FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
Devices Drug Delivery Endocrinology FDA
 HSMN NewsFeed - 21 Sep 2007
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 24 Jun 2007
BYETTA(R) Study Showed Comparable Blood Glucose Control to Insulin
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Jun 2007
SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Jun 2007
BYETTA(R) Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Mar 2007
Alkermes Announces Senior Management Succession Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2007
New Storage Instructions Approved for BYETTA(R)
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 30 Jan 2007
Amylin Pharmaceuticals Announces Appointment of Daniel M. Bradbury as Chief Executive Officer Effective March 1, 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2007
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 22 Dec 2006
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 21 Nov 2006
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 24 Oct 2006
Amylin Pharmaceuticals Expands Clinical Program in Obesity
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2006
Amylin Pharmaceuticals Appoints Joe Young Sr. Vice President, Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2006
Exenatide Receives Positive Opinion From the European Committee for Medicinal Products for Human Use for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Sep 2006
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 7 Sep 2006
SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 26 Jun 2006
Nastech Pharmaceutical Company Inc. Enters into Development and License Agreement With Amylin Pharmaceuticals, Inc.
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 19

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 19 additional stories matching:
exenatide
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.